Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mounjaro

Phase 2Small molecule

Mounjaro is one of 49 small molecule programs targeting Hyperplasia. It is currently in Phase 2.

2

Indications

2

Total Trials

2

Active Trials

48

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaNot yet recruiting

Weight LossRecruiting

HyperplasiaPhase 2

Not yet recruiting

Weight LossPhase 1

Recruiting

Competition

Competitive Landscape

35 competitors in Weight Loss

#DrugCompanyPhaseTrials

Victoza

Ozempic

Farxiga

Glucophage

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Topamax

Xifaxan

Invokana

Megace

Bristol-Myers Squibb

Versed

CConrado Roberto Hoffmann Filho

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Weight Loss

NCT06734273

Q1 2032

Phase 2Not yet recruiting

Hyperplasia

NCT06073184

Clinical

Trials by Indication[1]

Weight loss1 trial

Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss

Recruiting·NNicholas Skertich·Phase 1·NCT06734273·42 enrolled

Hyperplasia1 trial

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium

Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06073184·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mounjaro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mounjaro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mounjaro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

Related News